Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.79	3.04	2.18	2.13	6.97	15.17
Cash & Short-Term Investments	1.79	3.04	2.18	2.13	6.97	15.17
Cash Growth	-35.73%	39.77%	2.31%	-69.48%	-54.08%	51.95%
Receivables	-	0.31	-	-	-	-
Prepaid Expenses	4.42	2.17	1.89	2	2.46	2.12
Total Current Assets	6.2	5.52	4.06	4.13	9.43	17.29
Property, Plant & Equipment	20.82	21.6	20.38	21.46	19.64	19.92
Goodwill	0.63	0.63	0.63	0.63	0.63	0.63
Other Intangible Assets	52.05	53.19	1.29	1.29	1.29	1.29
Other Long-Term Assets	0.35	0.36	0.37	0.36	0.35	1.04
Total Assets	80.05	81.29	26.73	27.87	31.32	40.16

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	31.58	30.82	16.97	10.24	10.69	6.98
Accrued Expenses	-	-	4.45	-	-	-
Short-Term Debt	11.65	9.47	14.19	3.94	15.4	7.1
Current Portion of Long-Term Debt	31.57	32.7	20.19	16.54	0.14	0.14
Current Portion of Leases	0.27	0.37	0.33	0.31	0.35	0.32
Other Current Liabilities	7.9	18.35	12.15	14.17	99.43	119.24
Total Current Liabilities	82.97	91.7	68.27	45.2	126.01	133.77
Long-Term Debt	16.21	17.88	28.3	20.31	5.99	25.16
Long-Term Leases	4.29	4.41	4.44	4.45	4.37	5.23
Long-Term Deferred Tax Liabilities	12.94	13.17	-	-	-	-
Other Long-Term Liabilities	1.7	1.7	4.7	4.95	-	-
Total Liabilities	118.11	128.86	105.71	74.92	136.37	164.15

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1.62	1.57	1.33	1.18	1.07	0.95
Additional Paid-In Capital	1,455	1,443	1,345	1,291	1,165	1,067
Retained Earnings	-1,507	-1,504	-1,443	-1,360	-1,297	-1,192
Treasury Stock	-0.01	-0.01	-	-	-	-
Comprehensive Income & Other	-0.51	-1	2.96	1.46	3.07	0.28
Total Common Equity	-50.54	-60.28	-94.49	-65.77	-128.1	-123.99
Shareholders' Equity	-38.06	-47.57	-78.98	-47.06	-105.04	-123.99
Total Liabilities & Equity	80.05	81.29	26.73	27.87	31.32	40.16

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	63.99	64.83	67.44	45.56	26.25	37.94
Net Cash (Debt)	-62.21	-61.79	-65.27	-43.43	-19.29	-22.77
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.04	-0.04	-0.05	-0.04	-0.02	-0.02
Filing Date Shares Outstanding	1,643	1,607	1,391	1,190	1,073	960.02
Total Common Shares Outstanding	1,607	1,567	1,329	1,176	1,068	948.45
Working Capital	-76.77	-86.18	-64.21	-41.08	-116.58	-116.48
Book Value Per Share	-0.03	-0.04	-0.07	-0.06	-0.12	-0.13
Tangible Book Value	-103.22	-114.09	-96.41	-67.69	-130.02	-125.91
Tangible Book Value Per Share	-0.06	-0.07	-0.07	-0.06	-0.12	-0.13
Land	0.09	0.09	0.09	0.09	0.08	0.09
Machinery	5.91	5.92	3.69	3.26	2.54	2.11
Construction In Progress	-	-	-	-	2.03	-
Leasehold Improvements	18.92	19.08	17.97	17.79	13.07	13.91

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 2, 2026

Data Sources Report a data error